137 Stock Overview
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Aldeyra Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.95 |
| 52 Week High | US$6.42 |
| 52 Week Low | US$1.30 |
| Beta | 0.90 |
| 1 Month Change | -8.99% |
| 3 Month Change | -69.05% |
| 1 Year Change | -43.73% |
| 3 Year Change | -22.87% |
| 5 Year Change | -53.28% |
| Change since IPO | -60.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 137 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.9% | -1.4% | -0.9% |
| 1Y | -43.7% | -12.5% | 14.1% |
Return vs Industry: 137 underperformed the German Biotechs industry which returned -13.4% over the past year.
Return vs Market: 137 underperformed the German Market which returned 15.8% over the past year.
Price Volatility
| 137 volatility | |
|---|---|
| 137 Average Weekly Movement | 26.8% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 137's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 137's weekly volatility has increased from 16% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 8 | Todd Brady | www.aldeyra.com |
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication.
Aldeyra Therapeutics, Inc. Fundamentals Summary
| 137 fundamental statistics | |
|---|---|
| Market cap | €118.63m |
| Earnings (TTM) | -€50.79m |
| Revenue (TTM) | n/a |
Is 137 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 137 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$57.70m |
| Earnings | -US$57.70m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 23.7% |
How did 137 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 11:13 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aldeyra Therapeutics, Inc. is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Esther Lannie Hong | Berenberg |
| Thomas Shrader | BTIG |